Induction of renal kallikrein and renin gene expression by insulin and IGF-I in the diabetic rat.
The renal kallikrein-kinin system and the renin-angiotensin system are implicated in the pathogenesis of diabetic nephropathy. We have shown that renal kallikrein and renin gene expression are altered by diabetes. To investigate the cellular mechanisms responsible for these changes, we examined the effects of acute insulin and insulin-like growth factor I (IGF-I) treatment on renal kallikrein-kinin and renin-angiotensin system components. Three weeks after induction of diabetes, we measured renal kallikrein and renin mRNA levels, renal kallikrein and renal renin activity, and plasma renin activity in control and diabetic rats and diabetic rats treated with insulin or IGF-I for 2 or 5 h. In diabetic rats, kallikrein and renin mRNA levels were reduced >50% compared with control rats. Renal tissue kallikrein levels and plasma renin activity were decreased, whereas renal renin content was unchanged. Insulin increased kallikrein and renin mRNA levels after 2 h. IGF-I, at a dosage that stimulated kallikrein mRNA levels in control rats, had no effect on renal kallikrein and renin content or mRNA levels in diabetic rats. However, infusion of a fivefold higher IGF-I dosage resulted in a two- to threefold increase in kallikrein and renin mRNA levels in 2 h. These data suggest that 1) diabetes suppresses kallikrein and renin gene expression, and these abnormalities are reversed by insulin or IGF-I; and 2) the diabetic state produces resistance to IGF-I induction of kallikrein and renin gene expression. These changes in regulated synthesis of kallikrein and renin in the kidney may underlie renal vascular changes that develop in diabetes.
Jaffa
A A
AA
Department of Medicine, Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, South Carolina 29425, USA. jaffa@musc.edu
Vio
C
C
Velarde
V
V
LeRoith
D
D
Mayfield
R K
RK
D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000201:enzymology*; D015870:Gene Expression / Q000187:drug effects*; D007150:Immunohistochemistry; D007328:Insulin / Q000494:pharmacology*; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D007610:Kallikreins / Q000032:analysis / Q000235:genetics* / Q000378:metabolism; D007668:Kidney / Q000201:enzymology*; D008297:Male; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012083:Renin / Q000032:analysis / Q000235:genetics* / Q000378:metabolism
D007328:Insulin; D012333:RNA, Messenger; D007334:Insulin-Like Growth Factor I; D007610:Kallikreins; D012083:Renin